Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 1 2Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 7INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Melanoma 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Electroporation × Clear all
NCT02531425 2023-05-15

TNBC

OncoSec Medical Incorporated

Phase 1 Completed
10 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01045915 2015-09-11

AMEP

Valerio Therapeutics

Phase 1 Terminated
5 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡